ArticleScientific reports2025
The use of angiotensin-converting enzyme inhibitors in hospitalized patients with COVID-19 is associated with a lower risk of mortality.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Do angiotensin-converting enzyme inhibitors reduce the risk of death in COVID-19? Yes.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The relationship between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), diabetes mellitus (DM), and the risk of death in patients with COVID-19 remains controversial. We hypothesized that DM and certain characteristics of the COVID-19 course during hospital treatment may alter the assessment of the association of ACEIs/ARBs with COVID-19 outcomes. The records of 153 COVID-19 inpatients admitted to a municipal clinic in Kyiv, Ukraine, between October and December 2021 were reviewed. To assess the association of ARBs/ACEIs and other hypotensive drugs with outcomes, a no hypotensives group was used for comparison. A multivariable logistic regression model was employed to assess the odds ratio (OR) of death. If DM was known at the time of hospitalization (n = 28), there was a higher proportion of deaths compared to the group without DM (n = 125): 53.6% vs. 12.8%, p < 0.001. After adjusting for age, minimal O2 saturation, DM, and antihypertensive therapy, the ACEIs-associated OR was 0.10 (0.02-0.69). The DM-associated OR was 8.25 (1.92-35.42). The use of ACEIs in the treatment of COVID-19 inpatients is associated with a lower risk of mortality compared to those not using hypotensive treatment, regardless of the presence of DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.